Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCT241533 is an effective and selective ATP competitive inhibitor of CHK2 (Ki: 1.16 nM; IC50: 3 nM). 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 CCT241533 hydrochloride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 8-10周 | ||
50 mg | ¥ 13,800 | 8-10周 | ||
100 mg | ¥ 17,500 | 8-10周 |
CCT241533 的其他形式现货产品:
产品描述 | CCT241533 is an effective and selective ATP competitive inhibitor of CHK2 (Ki: 1.16 nM; IC50: 3 nM). |
靶点活性 | Chk1:245 nM, Chk2:3 nM |
体外活性 | CCT241533 inhibits CHK2 (IC50: 3 nM) and shows minimal cross-reactivity against a panel of kinases at 1 μM. X-ray crystallography confirms that CCT241533 binds to CHK2 in the ATP pocket. CCT241533 blocks CHK2 activity in human tumor cell lines in response to DNA damage. CCT241533 does not potentiate the cytotoxicity of a selection of genotoxic agents in several cell lines. However, CCT241533 significantly potentiates the cytotoxicity of two structurally distinct PARP inhibitors. Clear induction of the pS516 CHK2 signal is seen with a PARP inhibitor alone and this activation is abolished by CCT241533. In HT-29, HeLa, and MCF-7, the cytotoxicity of CCT241533 (GI50) is 1.7, 2.2, and 5.1 μM, respectively [1]. CCT241533 hydrochloride is a potent CHK2 inhibitor (IC50: 3 nM), with selectivity (63-fold) over CHK1(IC50: 190 nM) and low hERG inhibition (IC50: 22 μM) [2]. |
分子量 | 442.48 |
分子式 | C23H27FN4O4 |
CAS No. | 1262849-73-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CCT241533 1262849-73-9 Cell Cycle/Checkpoint Chk CCT 241533 CCT-241533 Inhibitor inhibitor inhibit